OMNISCAN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Omniscan, and when can generic versions of Omniscan launch?
Omniscan is a drug marketed by Ge Healthcare and is included in two NDAs.
The generic ingredient in OMNISCAN is gadodiamide. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the gadodiamide profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OMNISCAN?
- What are the global sales for OMNISCAN?
- What is Average Wholesale Price for OMNISCAN?
Summary for OMNISCAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 91 |
| Clinical Trials: | 6 |
| Patent Applications: | 1,341 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for OMNISCAN |
| What excipients (inactive ingredients) are in OMNISCAN? | OMNISCAN excipients list |
| DailyMed Link: | OMNISCAN at DailyMed |
Recent Clinical Trials for OMNISCAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Guerbet | Phase 4 |
| Bracco (Sponsor) | Phase 4 |
| IQVIA (Sponsor) | Phase 4 |
Pharmacology for OMNISCAN
| Drug Class | Paramagnetic Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
US Patents and Regulatory Information for OMNISCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | OMNISCAN | gadodiamide | INJECTABLE;INJECTION | 022066-001 | Sep 5, 2007 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ge Healthcare | OMNISCAN | gadodiamide | INJECTABLE;INJECTION | 022066-002 | Sep 5, 2007 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ge Healthcare | OMNISCAN | gadodiamide | INJECTABLE;INJECTION | 020123-001 | Jan 8, 1993 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OMNISCAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | OMNISCAN | gadodiamide | INJECTABLE;INJECTION | 020123-001 | Jan 8, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | OMNISCAN | gadodiamide | INJECTABLE;INJECTION | 022066-001 | Sep 5, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | OMNISCAN | gadodiamide | INJECTABLE;INJECTION | 022066-002 | Sep 5, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | OMNISCAN | gadodiamide | INJECTABLE;INJECTION | 022066-002 | Sep 5, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| Ge Healthcare | OMNISCAN | gadodiamide | INJECTABLE;INJECTION | 020123-001 | Jan 8, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OMNISCAN
See the table below for patents covering OMNISCAN around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Ireland | 56857 | PHYSIOLOGICALLY TOLERABLE METAL COMPLEX SALTS FOR USE IN NMR DIAGNOSIS | ⤷ Sign Up |
| Netherlands | 194579 | ⤷ Sign Up | |
| European Patent Office | 0169299 | USE OF PARAMAGNETIC COMPLEX SALTS FOR THE PREPARATION OF AGENTS FOR NMR DIAGNOSTICS | ⤷ Sign Up |
| Netherlands | 9900020 | ⤷ Sign Up | |
| Japan | S62501412 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OMNISCAN
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0216511 | 94C0015 | Belgium | ⤷ Sign Up | PRODUCT NAME: GADODIAMIDE; NAT. REGISTRATION NO/DATE: NL 19253 19940425; FIRST REGISTRATION: GB - 0637/0015 19920925 |
| 0071564 | SPC/GB93/060 | United Kingdom | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
